Literature DB >> 2187121

Immunocytochemical evaluation of abl-gene products in leukemic cell lines.

S Kitazawa1, S Maeda, T Sugiyama.   

Abstract

We raised monoclonal antibody (MAb) against a synthetic oligopeptide corresponding to a portion of the predicted v-abl protein sequence (379-390). This MAb reacted with all of the abl-gene products (p145c-abl, p150c-abl and p210bcr-abl fused protein) and was not specific for any one of them. Immunocytochemically, we investigated the expression and localization of the abl-gene products in various leukemic cell lines. Positive immunoreactions were observed in Ph1 positive leukemic cell lines (K562 and KU-812) and erythro-leukemic cell lines (HEL and K3D) and were located on the cell membrane. Electron microscopically, a different distribution pattern was observed among the cell lines: linear and almost even in Ph1 positive leukemic cell lines, whereas spotted or budding-like in erythroleukemic cell lines. Ph1 translocation produces p210bcr-abl fused protein with not only altered autophosphorylation activities but also altered subcellular distribution patterns.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2187121     DOI: 10.1007/bf03000489

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  20 in total

1.  Fused transcript of abl and bcr genes in chronic myelogenous leukaemia.

Authors:  E Shtivelman; B Lifshitz; R P Gale; E Canaani
Journal:  Nature       Date:  1985 Jun 13-19       Impact factor: 49.962

2.  Expression of the 21,000 molecular weight ras protein in a spectrum of benign and malignant human mammary tissues.

Authors:  N Ohuchi; A Thor; D L Page; P H Hand; S A Halter; J Schlom
Journal:  Cancer Res       Date:  1986-05       Impact factor: 12.701

3.  Molecular recognition and the future of monoclonal antibodies.

Authors:  D Lane; H Koprowski
Journal:  Nature       Date:  1982-03-18       Impact factor: 49.962

4.  Chromosomal localization of human cellular homologues of two viral oncogenes.

Authors:  N Heisterkamp; J Groffen; J R Stephenson; N K Spurr; P N Goodfellow; E Solomon; B Carritt; W F Bodmer
Journal:  Nature       Date:  1982-10-21       Impact factor: 49.962

5.  Monoclonal antibodies of predefined specificity detect activated ras gene expression in human mammary and colon carcinomas.

Authors:  P H Hand; A Thor; D Wunderlich; R Muraro; A Caruso; J Schlom
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

6.  Monoclonal antibodies to the p21 products of the transforming gene of Harvey murine sarcoma virus and of the cellular ras gene family.

Authors:  M E Furth; L J Davis; B Fleurdelys; E M Scolnick
Journal:  J Virol       Date:  1982-07       Impact factor: 5.103

7.  Identification of molecular variants of p210bcr-abl in chronic myelogenous leukemia.

Authors:  R Kurzrock; W S Kloetzer; M Talpaz; M Blick; R Walters; R B Arlinghaus; J U Gutterman
Journal:  Blood       Date:  1987-07       Impact factor: 22.113

8.  Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22.

Authors:  J Groffen; J R Stephenson; N Heisterkamp; A de Klein; C R Bartram; G Grosveld
Journal:  Cell       Date:  1984-01       Impact factor: 41.582

9.  Nucleotide sequence of Abelson murine leukemia virus genome: structural similarity of its transforming gene product to other onc gene products with tyrosine-specific kinase activity.

Authors:  E P Reddy; M J Smith; A Srinivasan
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

10.  Chromosomal translocations activating myc sequences and transduction of v-abl are critical events in the rapid induction of plasmacytomas by pristane and abelson virus.

Authors:  S Ohno; S Migita; F Wiener; M Babonits; G Klein; J F Mushinski; M Potter
Journal:  J Exp Med       Date:  1984-06-01       Impact factor: 14.307

View more
  1 in total

1.  Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.

Authors:  M Wetzler; M Talpaz; R A Van Etten; C Hirsh-Ginsberg; M Beran; R Kurzrock
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.